hydroxychloroquine has been researched along with Critical Illness in 29 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with hydroxychloroquine (HCQ) and lopinavir/ritonavir did not show any mortality benefit in either the RECOVERY or World Health Organization (WHO) Solidarity trials." | 2.72 | Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. ( Emani, SR; Emani, VR; Goswami, S; Nandanoor, D; Reddy, NK; Reddy, R, 2021) |
| "The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic." | 2.66 | Clinical management of COVID-19. ( Abraham, OC; John, R; Karthik, R; Manesh, A; Varghese, GM, 2020) |
| " The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events." | 2.66 | Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. ( An, MH; Hwang, TH; Kim, MS; Kim, WJ, 2020) |
| "6% probability of improving 6-month survival across varying hydrocortisone dosing strategies." | 1.91 | Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. ( Al-Beidh, F; Angus, DC; Annane, D; Arabi, YM; Beane, A; Berry, LR; Berry, S; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Burrell, A; Buxton, M; Buzgau, A; Charles, WN; Cove, M; Derde, LPG; Detry, MA; Estcourt, LJ; Fagbodun, EO; Fitzgerald, M; Girard, TD; Goligher, EC; Goossens, H; Gordon, AC; Green, C; Haniffa, R; Higgins, AM; Hills, T; Horvat, CM; Huang, DT; Ichihara, N; Lamontagne, F; Lawler, PR; Lewis, RJ; Lorenzi, E; Marshall, JC; McArthur, CJ; McAuley, DF; McGlothlin, A; McGuinness, SP; McQuilten, Z; McVerry, BJ; Mouncey, PR; Murthy, S; Neal, MD; Nichol, AD; Parke, RL; Parker, JC; Parry-Billings, K; Peters, SEC; Reyes, LF; Rowan, KM; Saito, H; Santos, MS; Saunders, CT; Serpa-Neto, A; Seymour, CW; Shankar-Hari, M; Stronach, LM; Turgeon, AF; Turner, AM; van Bentum-Puijk, W; van de Veerdonk, FL; Webb, SA; Zarychanski, R, 2023) |
| " This was a retrospective, observational, multicentre, pharmacokinetic study of HCQ in critically ill COVID-19 patients." | 1.62 | Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ( Baklouti, S; Concordet, D; Conil, JM; Gandia, P; Georges, B; Goudy, P; Lanot, T; Lavit, M; Losha, E; Mané, C; Minville, V; Rousset, D; Ruiz, S; Vinour, H, 2021) |
| " Lower white blood cell count and lactate dehydrogenase at the time of drug administration as well as shorter time from supplemental oxygen initiation to dosing were significantly associated with clinical improvement in the univariate analysis." | 1.62 | Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. ( Daniel, NM; Hilden, P; Raja, K; Smoke, SM, 2021) |
| "Hydroxychloroquine (HCQ) was used by 78." | 1.56 | Early impact of COVID-19 on transplant center practices and policies in the United States. ( Avery, RK; Boyarsky, BJ; Durand, CM; Garonzik-Wang, JM; Getsin, SN; Jackson, KR; Kernodle, AB; Massie, AB; Po-Yu Chiang, T; Segev, DL; Van Pilsum Rasmussen, SE; Werbel, WA, 2020) |
| "One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure." | 1.56 | Early experience with remdesivir in SARS-CoV-2 pneumonia. ( Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R, 2020) |
| "It may cause severe viral pneumonia with Acute Respiratory Distress Syndrome requiring critical care." | 1.56 | Very severe COVID-19 in the critically ill in Tunisia. ( Boussarsar, M; Ennouri, E; Jerbi, S; Mahmoud, J; Meddeb, K; Nachi, R; Saida, IB; Thabet, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 28 (96.55) | 2.80 |
| Authors | Studies |
|---|---|
| Dal-Ré, R | 1 |
| Porcher, R | 1 |
| Ravaud, P | 1 |
| Resche-Rigon, M | 1 |
| Tharaux, PL | 1 |
| Mariette, X | 1 |
| Hermine, O | 1 |
| Higgins, AM | 3 |
| Berry, LR | 3 |
| Lorenzi, E | 3 |
| Murthy, S | 3 |
| McQuilten, Z | 2 |
| Mouncey, PR | 3 |
| Al-Beidh, F | 2 |
| Annane, D | 3 |
| Arabi, YM | 3 |
| Beane, A | 3 |
| van Bentum-Puijk, W | 2 |
| Bhimani, Z | 3 |
| Bonten, MJM | 3 |
| Bradbury, CA | 3 |
| Brunkhorst, FM | 3 |
| Burrell, A | 2 |
| Buzgau, A | 3 |
| Buxton, M | 3 |
| Charles, WN | 2 |
| Cove, M | 2 |
| Detry, MA | 3 |
| Estcourt, LJ | 3 |
| Fagbodun, EO | 2 |
| Fitzgerald, M | 3 |
| Girard, TD | 3 |
| Goligher, EC | 3 |
| Goossens, H | 3 |
| Haniffa, R | 3 |
| Hills, T | 2 |
| Horvat, CM | 3 |
| Huang, DT | 3 |
| Ichihara, N | 2 |
| Lamontagne, F | 3 |
| Marshall, JC | 3 |
| McAuley, DF | 3 |
| McGlothlin, A | 3 |
| McGuinness, SP | 2 |
| McVerry, BJ | 3 |
| Neal, MD | 2 |
| Nichol, AD | 3 |
| Parke, RL | 2 |
| Parker, JC | 3 |
| Parry-Billings, K | 2 |
| Peters, SEC | 2 |
| Reyes, LF | 2 |
| Rowan, KM | 3 |
| Saito, H | 2 |
| Santos, MS | 3 |
| Saunders, CT | 3 |
| Serpa-Neto, A | 2 |
| Seymour, CW | 3 |
| Shankar-Hari, M | 3 |
| Stronach, LM | 2 |
| Turgeon, AF | 3 |
| Turner, AM | 3 |
| van de Veerdonk, FL | 3 |
| Zarychanski, R | 3 |
| Green, C | 3 |
| Lewis, RJ | 2 |
| Angus, DC | 3 |
| McArthur, CJ | 2 |
| Berry, S | 3 |
| Derde, LPG | 3 |
| Gordon, AC | 3 |
| Webb, SA | 3 |
| Lawler, PR | 3 |
| Morin, C | 1 |
| Padki, A | 1 |
| Wong, A | 1 |
| Miano, T | 1 |
| Kane-Gill, SL | 1 |
| Cozzi, G | 1 |
| Deveau, R | 1 |
| Atluri, S | 1 |
| Manchikanti, L | 1 |
| Hirsch, JA | 1 |
| Boyarsky, BJ | 1 |
| Po-Yu Chiang, T | 1 |
| Werbel, WA | 1 |
| Durand, CM | 1 |
| Avery, RK | 1 |
| Getsin, SN | 1 |
| Jackson, KR | 1 |
| Kernodle, AB | 1 |
| Van Pilsum Rasmussen, SE | 1 |
| Massie, AB | 1 |
| Segev, DL | 1 |
| Garonzik-Wang, JM | 1 |
| Yu, B | 2 |
| Li, C | 2 |
| Chen, P | 2 |
| Zhou, N | 1 |
| Wang, L | 1 |
| Li, J | 2 |
| Jiang, H | 2 |
| Wang, DW | 2 |
| Durante-Mangoni, E | 1 |
| Andini, R | 1 |
| Bertolino, L | 1 |
| Mele, F | 1 |
| Florio, LL | 1 |
| Murino, P | 1 |
| Corcione, A | 1 |
| Zampino, R | 1 |
| Edelstein, CL | 1 |
| Venkatachalam, MA | 1 |
| Dong, Z | 1 |
| Hossri, S | 1 |
| Shadi, M | 1 |
| Hamarsha, Z | 1 |
| Schneider, R | 1 |
| El-Sayegh, D | 1 |
| Painvin, B | 1 |
| Guillot, P | 1 |
| Verdier, MC | 1 |
| Gacouin, A | 1 |
| Maamar, A | 1 |
| Varghese, GM | 1 |
| John, R | 1 |
| Manesh, A | 1 |
| Karthik, R | 1 |
| Abraham, OC | 1 |
| Lecronier, M | 1 |
| Beurton, A | 1 |
| Burrel, S | 1 |
| Haudebourg, L | 1 |
| Deleris, R | 1 |
| Le Marec, J | 1 |
| Virolle, S | 1 |
| Nemlaghi, S | 1 |
| Bureau, C | 1 |
| Mora, P | 1 |
| De Sarcus, M | 1 |
| Clovet, O | 1 |
| Duceau, B | 1 |
| Grisot, PH | 1 |
| Pari, MH | 1 |
| Arzoine, J | 1 |
| Clarac, U | 1 |
| Boutolleau, D | 1 |
| Raux, M | 1 |
| Delemazure, J | 1 |
| Faure, M | 1 |
| Decavele, M | 1 |
| Morawiec, E | 1 |
| Mayaux, J | 1 |
| Demoule, A | 1 |
| Dres, M | 1 |
| Faden, YA | 1 |
| Alghilan, NA | 1 |
| Alawami, SH | 1 |
| Alsulmi, ES | 1 |
| Alsum, HA | 1 |
| Katib, YA | 1 |
| Sabr, YS | 1 |
| Tahir, FH | 1 |
| Bondagji, NS | 1 |
| Farooqi, FI | 1 |
| Morgan, RC | 1 |
| Dhawan, N | 1 |
| Dinh, J | 1 |
| Yatzkan, G | 1 |
| Michel, G | 1 |
| Bartoletti, M | 2 |
| Marconi, L | 1 |
| Scudeller, L | 1 |
| Pancaldi, L | 1 |
| Tedeschi, S | 1 |
| Giannella, M | 1 |
| Rinaldi, M | 1 |
| Bussini, L | 1 |
| Valentini, I | 1 |
| Ferravante, AF | 1 |
| Potalivo, A | 1 |
| Marchionni, E | 1 |
| Fornaro, G | 1 |
| Pascale, R | 1 |
| Pasquini, Z | 1 |
| Puoti, M | 1 |
| Merli, M | 1 |
| Barchiesi, F | 1 |
| Volpato, F | 1 |
| Rubin, A | 1 |
| Saracino, A | 1 |
| Tonetti, T | 2 |
| Gaibani, P | 2 |
| Ranieri, VM | 2 |
| Viale, P | 2 |
| Cristini, F | 1 |
| Emani, VR | 1 |
| Goswami, S | 1 |
| Nandanoor, D | 1 |
| Emani, SR | 1 |
| Reddy, NK | 1 |
| Reddy, R | 1 |
| Saida, IB | 1 |
| Ennouri, E | 1 |
| Nachi, R | 1 |
| Meddeb, K | 1 |
| Mahmoud, J | 1 |
| Thabet, N | 1 |
| Jerbi, S | 1 |
| Boussarsar, M | 1 |
| Ruiz, S | 1 |
| Concordet, D | 1 |
| Lanot, T | 1 |
| Georges, B | 1 |
| Goudy, P | 1 |
| Baklouti, S | 1 |
| Mané, C | 1 |
| Losha, E | 1 |
| Vinour, H | 1 |
| Rousset, D | 1 |
| Lavit, M | 1 |
| Minville, V | 1 |
| Conil, JM | 1 |
| Gandia, P | 1 |
| Jiménez-Jáimez, J | 1 |
| Macías-Ruiz, R | 1 |
| Bermúdez-Jiménez, F | 1 |
| Rubini-Costa, R | 1 |
| Ramírez-Taboada, J | 1 |
| Flores, PIG | 1 |
| Gallo-Padilla, L | 1 |
| García, JDM | 1 |
| García, CM | 1 |
| Suárez, SM | 1 |
| Molina, CF | 1 |
| López, MÁ | 1 |
| Tercedor, L | 1 |
| Smoke, SM | 1 |
| Raja, K | 1 |
| Hilden, P | 1 |
| Daniel, NM | 1 |
| Kim, MS | 1 |
| An, MH | 1 |
| Kim, WJ | 1 |
| Hwang, TH | 1 |
| Re, MC | 1 |
| Bahl, A | 1 |
| Johnson, S | 1 |
| Chen, NW | 1 |
| Alser, O | 1 |
| Mokhtari, A | 1 |
| Naar, L | 1 |
| Langeveld, K | 1 |
| Breen, KA | 1 |
| El Moheb, M | 1 |
| Kapoen, C | 1 |
| Gaitanidis, A | 1 |
| Christensen, MA | 1 |
| Maurer, LR | 1 |
| Mashbari, H | 1 |
| Bankhead-Kendall, B | 1 |
| Parks, J | 1 |
| Fawley, J | 1 |
| Saillant, N | 1 |
| Mendoza, A | 1 |
| Paranjape, C | 1 |
| Fagenholz, P | 1 |
| King, D | 1 |
| Lee, J | 1 |
| Farhat, MR | 1 |
| Velmahos, GC | 1 |
| Kaafarani, HMA | 1 |
| Corominas, H | 1 |
| Castellví, I | 1 |
| Diaz-Torné, C | 1 |
| Matas, L | 1 |
| de la Rosa, D | 1 |
| Mangues, MA | 1 |
| Moya, P | 1 |
| Pomar, V | 1 |
| Benito, N | 1 |
| Moga, E | 1 |
| Sosa, NH | 1 |
| Casademont, J | 1 |
| Domingo, P | 1 |
| Beidh, FA | 1 |
| Swaidan, LA | 1 |
| Beasley, R | 1 |
| Cheng, A | 1 |
| De Jong, M | 1 |
| Duffy, EJ | 1 |
| Fowler, R | 1 |
| Hills, TE | 1 |
| King, AJ | 1 |
| Lewis, R | 1 |
| Linstrum, K | 1 |
| Litton, E | 1 |
| Malakouti, S | 1 |
| Mcguinness, S | 1 |
| Montgomery, SK | 1 |
| Morpeth, SC | 1 |
| Orr, K | 1 |
| Parke, R | 1 |
| Patanwala, AE | 1 |
| Tong, SYC | 1 |
| McArthur, C | 1 |
| Maddison, PJ | 1 |
| Thorpe, C | 1 |
| Seale, JR | 1 |
| Ahmed, W | 1 |
| Whiteley, GS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients[NCT04324047] | 1,000 participants (Anticipated) | Observational | 2020-03-27 | Recruiting | |||
| Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19[NCT05132972] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2021-01-17 | Recruiting | ||
| Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients[NCT04437823] | Phase 2 | 5 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study[NCT04380870] | 500 participants (Anticipated) | Observational | 2020-05-11 | Recruiting | |||
| Non-ventilated Prone Positioning in the COVID-19 Population[NCT05957588] | 216 participants (Actual) | Interventional | 2021-10-01 | Completed | |||
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia[NCT02735707] | Phase 3 | 10,000 participants (Anticipated) | Interventional | 2016-04-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxychloroquine and Critical Illness
| Article | Year |
|---|---|
Clinical management of COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Airway Management; Alanine; Antibodies, Monoclonal | 2020 |
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
Topics: COVID-19; COVID-19 Drug Treatment; Critical Illness; Hospitalization; Humans; Hydroxychloroquine; Lo | 2021 |
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Azithromycin; COVID-19; COVID-19 Drug Tr | 2020 |
1 trial available for hydroxychloroquine and Critical Illness
| Article | Year |
|---|---|
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Topics: Adult; Antiviral Agents; Bayes Theorem; COVID-19 Drug Treatment; Critical Illness; Drug Combinations | 2021 |
25 other studies available for hydroxychloroquine and Critical Illness
| Article | Year |
|---|---|
COVID-19 drug research and the cohort multiple randomised controlled trial design.
Topics: Adult; COVID-19; Critical Illness; Humans; Hydroxychloroquine; Receptors, Interleukin-6; SARS-CoV-2 | 2022 |
Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design.
Topics: Adult; COVID-19; Critical Illness; Humans; Hydroxychloroquine; Receptors, Interleukin-6; SARS-CoV-2 | 2022 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Bayes Theorem; COVID-19; COVID-19 Serotherapy; Criti | 2023 |
Comparison of COVID-19 Preprint and Peer-Reviewed Versions of Studies on Therapies for Critically Ill Patients.
Topics: COVID-19; Critical Illness; Humans; Hydroxychloroquine; Pandemics; Reproducibility of Results | 2023 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Early impact of COVID-19 on transplant center practices and policies in the United States.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Betacoronavirus; Clinical Labor | 2020 |
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
Topics: China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Humans; Hydroxyc | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver | 2020 |
Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19.
Topics: Acute Kidney Injury; Autophagy; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Crit | 2020 |
Clinically significant anticardiolipin antibodies associated with COVID-19.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiphospholi | 2020 |
Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.
Topics: Acute Kidney Injury; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
Topics: Aged; Coronavirus Infections; COVID-19; Critical Illness; Drug Combinations; Female; Humans; Hydroxy | 2020 |
Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs.
Topics: Aged; Antimalarials; Antiviral Agents; China; COVID-19 Drug Treatment; Critical Illness; Female; Hum | 2021 |
Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019.
Topics: Anticoagulants; Antiviral Agents; Betacoronavirus; Congenital Abnormalities; Coronavirus Infections; | 2020 |
Airway Hygiene in COVID-19 Pneumonia: Treatment Responses of 3 Critically Ill Cruise Ship Employees.
Topics: Aged; Antimalarials; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Tr | 2020 |
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical | 2021 |
Very severe COVID-19 in the critically ill in Tunisia.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COV | 2020 |
Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Bronchoalveolar Lavage Fluid; COVID-19 Drug Treatm | 2021 |
Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin | 2020 |
Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Ill | 2021 |
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Hu | 2021 |
Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; COVID-19; COVID-19 Drug Treatment; Critical Illness; Hospital | 2021 |
Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities.
Topics: Acute Kidney Injury; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Boston; Comorbidity | 2021 |
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Topics: Aged; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Azithromycin; Comorbidity; COVID-19; | 2021 |
'Catastrophic' antiphospholipid syndrome.
Topics: Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Critical | 2000 |